Hepatosplenic T-cell lymphoma and inflammatory bowel disease

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Objective: This article reviews the current literature and knowledge about hepatosplenic T-cell lymphoma (HSTCL), providing an overview of the clinical features, a description of its pathology and immunophenotypic traits in relation to other lymphomas. In addition, we explore the history of reported cases of hepatosplenic T-cell lymphoma in relation to the possible existence of a causal relationship between infliximab use and HSTCL. The treatments for HSTCL will be briefly addressed. Methods: A comprehensive literature search using multiple databases was performed. Keyword search phrases including "lymphoma," "hepatosplenic T-cell lymphoma," "Inflammatory bowel disease," "6-mercaptopurine," and "infliximab" were used in various combinations. In addition references from published papers were reviewed as well. Results: There are over 200 reported cases of HSTCL. Only 22 cases of hepatosplenic T-cell lymphoma are associated with IBD treatment. Clinicians usually reserve immunomodulators and biologics for moderate to severe IBD cases. The ultimate goal of therapy is to control inflammation and therefore allow mucosal healing. IBD patients demonstrating mucosal healing are less likely to undergo surgery and experience complications related to their disease. We manipulate the immune system with corticosteroids, immunomodulators, and biologics, therefore causing bone marrow suppression. With bone marrow suppression, malignant degeneration may begin through selective uncontrolled cell proliferation, initiating HSTCL development in the genetically susceptible. Conclusion: Hepatosplenic T-cell lymphoma is a rare disease, often with a poor outcome. With the increasing number of reported cases of HSTCL linked to the use of infliximab, adalimumab, and AZA/6-MP, there appears to be an undeniable association of HSTCL development with the use of these agents. This risk is unquantifiable. When considering the rarity of cases and the multiple complications with uncontrolled disease, however, the benefit of treatment far outweighs the risk.

Original languageEnglish (US)
Pages (from-to)511-522
Number of pages12
JournalJournal of Crohn's and Colitis
Volume4
Issue number5
DOIs
StatePublished - Nov 2010

Fingerprint

T-Cell Lymphoma
Inflammatory Bowel Diseases
Immunologic Factors
Biological Products
Lymphoma
Bone Marrow
6-Mercaptopurine
Therapeutics
Rare Diseases
Immune System
Adrenal Cortex Hormones
History
Cell Proliferation
Databases
Pathology
Inflammation

Keywords

  • 6-Mercaptopurine
  • Hepatosplenic T-cell lymphoma
  • Inflammatory bowel disease
  • Infliximab
  • Lymphoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hepatosplenic T-cell lymphoma and inflammatory bowel disease. / Thai, Anne; Prindiville, Thomas P.

In: Journal of Crohn's and Colitis, Vol. 4, No. 5, 11.2010, p. 511-522.

Research output: Contribution to journalArticle

@article{cce6190c82084c33b7aed58d661c4c9c,
title = "Hepatosplenic T-cell lymphoma and inflammatory bowel disease",
abstract = "Objective: This article reviews the current literature and knowledge about hepatosplenic T-cell lymphoma (HSTCL), providing an overview of the clinical features, a description of its pathology and immunophenotypic traits in relation to other lymphomas. In addition, we explore the history of reported cases of hepatosplenic T-cell lymphoma in relation to the possible existence of a causal relationship between infliximab use and HSTCL. The treatments for HSTCL will be briefly addressed. Methods: A comprehensive literature search using multiple databases was performed. Keyword search phrases including {"}lymphoma,{"} {"}hepatosplenic T-cell lymphoma,{"} {"}Inflammatory bowel disease,{"} {"}6-mercaptopurine,{"} and {"}infliximab{"} were used in various combinations. In addition references from published papers were reviewed as well. Results: There are over 200 reported cases of HSTCL. Only 22 cases of hepatosplenic T-cell lymphoma are associated with IBD treatment. Clinicians usually reserve immunomodulators and biologics for moderate to severe IBD cases. The ultimate goal of therapy is to control inflammation and therefore allow mucosal healing. IBD patients demonstrating mucosal healing are less likely to undergo surgery and experience complications related to their disease. We manipulate the immune system with corticosteroids, immunomodulators, and biologics, therefore causing bone marrow suppression. With bone marrow suppression, malignant degeneration may begin through selective uncontrolled cell proliferation, initiating HSTCL development in the genetically susceptible. Conclusion: Hepatosplenic T-cell lymphoma is a rare disease, often with a poor outcome. With the increasing number of reported cases of HSTCL linked to the use of infliximab, adalimumab, and AZA/6-MP, there appears to be an undeniable association of HSTCL development with the use of these agents. This risk is unquantifiable. When considering the rarity of cases and the multiple complications with uncontrolled disease, however, the benefit of treatment far outweighs the risk.",
keywords = "6-Mercaptopurine, Hepatosplenic T-cell lymphoma, Inflammatory bowel disease, Infliximab, Lymphoma",
author = "Anne Thai and Prindiville, {Thomas P}",
year = "2010",
month = "11",
doi = "10.1016/j.crohns.2010.05.006",
language = "English (US)",
volume = "4",
pages = "511--522",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Hepatosplenic T-cell lymphoma and inflammatory bowel disease

AU - Thai, Anne

AU - Prindiville, Thomas P

PY - 2010/11

Y1 - 2010/11

N2 - Objective: This article reviews the current literature and knowledge about hepatosplenic T-cell lymphoma (HSTCL), providing an overview of the clinical features, a description of its pathology and immunophenotypic traits in relation to other lymphomas. In addition, we explore the history of reported cases of hepatosplenic T-cell lymphoma in relation to the possible existence of a causal relationship between infliximab use and HSTCL. The treatments for HSTCL will be briefly addressed. Methods: A comprehensive literature search using multiple databases was performed. Keyword search phrases including "lymphoma," "hepatosplenic T-cell lymphoma," "Inflammatory bowel disease," "6-mercaptopurine," and "infliximab" were used in various combinations. In addition references from published papers were reviewed as well. Results: There are over 200 reported cases of HSTCL. Only 22 cases of hepatosplenic T-cell lymphoma are associated with IBD treatment. Clinicians usually reserve immunomodulators and biologics for moderate to severe IBD cases. The ultimate goal of therapy is to control inflammation and therefore allow mucosal healing. IBD patients demonstrating mucosal healing are less likely to undergo surgery and experience complications related to their disease. We manipulate the immune system with corticosteroids, immunomodulators, and biologics, therefore causing bone marrow suppression. With bone marrow suppression, malignant degeneration may begin through selective uncontrolled cell proliferation, initiating HSTCL development in the genetically susceptible. Conclusion: Hepatosplenic T-cell lymphoma is a rare disease, often with a poor outcome. With the increasing number of reported cases of HSTCL linked to the use of infliximab, adalimumab, and AZA/6-MP, there appears to be an undeniable association of HSTCL development with the use of these agents. This risk is unquantifiable. When considering the rarity of cases and the multiple complications with uncontrolled disease, however, the benefit of treatment far outweighs the risk.

AB - Objective: This article reviews the current literature and knowledge about hepatosplenic T-cell lymphoma (HSTCL), providing an overview of the clinical features, a description of its pathology and immunophenotypic traits in relation to other lymphomas. In addition, we explore the history of reported cases of hepatosplenic T-cell lymphoma in relation to the possible existence of a causal relationship between infliximab use and HSTCL. The treatments for HSTCL will be briefly addressed. Methods: A comprehensive literature search using multiple databases was performed. Keyword search phrases including "lymphoma," "hepatosplenic T-cell lymphoma," "Inflammatory bowel disease," "6-mercaptopurine," and "infliximab" were used in various combinations. In addition references from published papers were reviewed as well. Results: There are over 200 reported cases of HSTCL. Only 22 cases of hepatosplenic T-cell lymphoma are associated with IBD treatment. Clinicians usually reserve immunomodulators and biologics for moderate to severe IBD cases. The ultimate goal of therapy is to control inflammation and therefore allow mucosal healing. IBD patients demonstrating mucosal healing are less likely to undergo surgery and experience complications related to their disease. We manipulate the immune system with corticosteroids, immunomodulators, and biologics, therefore causing bone marrow suppression. With bone marrow suppression, malignant degeneration may begin through selective uncontrolled cell proliferation, initiating HSTCL development in the genetically susceptible. Conclusion: Hepatosplenic T-cell lymphoma is a rare disease, often with a poor outcome. With the increasing number of reported cases of HSTCL linked to the use of infliximab, adalimumab, and AZA/6-MP, there appears to be an undeniable association of HSTCL development with the use of these agents. This risk is unquantifiable. When considering the rarity of cases and the multiple complications with uncontrolled disease, however, the benefit of treatment far outweighs the risk.

KW - 6-Mercaptopurine

KW - Hepatosplenic T-cell lymphoma

KW - Inflammatory bowel disease

KW - Infliximab

KW - Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=77958152111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958152111&partnerID=8YFLogxK

U2 - 10.1016/j.crohns.2010.05.006

DO - 10.1016/j.crohns.2010.05.006

M3 - Article

C2 - 21122554

AN - SCOPUS:77958152111

VL - 4

SP - 511

EP - 522

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 5

ER -